A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw.
A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw.
This method offers the opportunity to simplify therapeutic drug monitoring of adalimumab.
“Easy home sampling at different time points will benefit patients and could help to prescribe biologics optimally,” said Dr. Karien Bloem, senior author of the British Journal of Clinical Pharmacology study.
Additional Information
Link to Study: http://onlinelibrary.wiley.com/doi/10.1111/bcp.13371/full
About Journal
The British Journal of Clinical Pharmacology (BJCP) contains papers and reports on all aspects of drug action in humans: invited review articles, original papers and correspondence. The journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry.
Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com